SBIR-STTR Award

Pharmaceutical Therapy For Seasonal Affective Disorder
Award last edited on: 7/19/10

Sponsored Program
SBIR
Awarding Agency
NIH : NIMH
Total Award Amount
$349,999
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Jay K Trautman

Company Information

Photoswitch Biosciences Inc

1600 Adams Drive Suite 105
Menlo Park, CA 94025
   (650) 773-2942
   info@photoswitchbio.com
   www.photoswitchbio.com
Location: Single
Congr. District: 18
County: San Mateo

Phase I

Contract Number: 1R43MH088062-01A1
Start Date: 5/1/10    Completed: 4/30/11
Phase I year
2010
Phase I Amount
$349,999
Seasonal Affective Disorder (SAD) is one of the most common mood disorders, affecting 1-3% of the population in temperate climates, predominantly women. Currently, there are no specific drug therapies for SAD. Patients are prescribed general anti-depressants or bright light therapy. SAD symptoms include low mood, loss of interest, difficulty concentrating, loss of energy and fatigue. In addition, SAD patients tend to have an increased appetite with associated weight gain and carbohydrate cravings, sweets in particular, in the afternoon or evening. There is often an intense daytime drowsiness in spite of increased sleep duration. SAD constitutes an unmet medical need. The prevalence of SAD and the absence of specific, efficacious and safe pharmacotherapy warrant initiation of a project to discover a therapeutic based in the biology the disease. The end goal of the proposed work is the development a pharmaceutical treatment for SAD by targeting the melanopsin-expressing, intrinsically photosensitive retinal ganglion cells (ipRGC) found in the mammalian retina. The pathway is biologically validated in that bright light therapy, which stimulates the ipRGCs, is efficacious in patients with SAD, and patients having a particular melanopsin mutation have been found to be ~6x more likely to have SAD. The pathway has at its apex, melanopsin, a G-protein coupled receptor (GPCR) that is only expressed in the target cells. A drug activating melanopsin should be able to entrain and shift the circadian pacemaker in the suprachiasmatic nucleus and thus would be invaluable as a drug to treat SAD, as well as jet lag, insomnia related to shift work, and sleep timing disorders. The proposed Specific Aims are (1) demonstrate luminescence reporter assay readout of activation of human melanopsin in 293T cells; (2) optimize the reporter system in several cell types; (3) identify by microarray analysis other, potentially better, reporters and evaluate their performance in the luminescence assay; and (4) adapt and validate the optimized assay from Aims 1-3 for a high-throughput screen for melanopsin agonists. There is, to our knowledge, no pharmaceutical precedent to this approach.

Public Health Relevance:
Millions of Americans suffer from a disease called Seasonal Affective Disorder (SAD). People with SAD exhibit classical symptoms of depression during the winter months, associated with the prolonged periods of darkness as are found in higher latitudes. Increasing evidence points to a disruption of the light-dark cycling that is inherent in humans as the primary cause of SAD. We are developing drugs that target the source of the light-dark cycling; cells in the eye that do not contribute to normal vision but detect whether it is night or day. Our therapy should be better than existing treatments, which are non-specific, as we are targeting the primary source of the disease.

Thesaurus Terms:
Accounting; Actinotherapy; Affect; Affective Disorders; Agonist; American; Appetite Stimulated; Area; Assay; Bioassay; Biologic Assays; Biological Assay; Biology; Cos Cells; Cos-1; Carbohydrates; Cell Communication And Signaling; Cell Cycle; Cell Division Cycle; Cell Line; Cell Lines, Strains; Cell Signaling; Cellline; Cells; Circadian Rhythms; Climate; Collection; Coupled; Darkness; Darknesses; Data; Development; Disease; Disorder; Diurnal Rhythm; Drowsiness; Drowsinesses; Drug Delivery; Drug Delivery Systems; Drug Targeting; Drug Targetings; Drug Therapy; Drugs; Emotional Depression; Enhancers; Exhibits; Eye; Eyeball; Fatigue; G Protein-Complex Receptor; G-Protein-Coupled Receptors; G-Proteins; Gtp-Binding Proteins; Gtp-Regulatory Proteins; Ganglion Cells (Retina); Genes; Genetic Alteration; Genetic Change; Genetic Defect; Goals; Guanine Nucleotide Coupling Protein; Guanine Nucleotide Regulatory Proteins; High Throughput Assay; Human; Human, General; Hypothalamic Structure; Hypothalamus; Immunologic, Luciferase; Increased Food Appetite; Industry; Insomnia; Insomnia Disorder; Intracellular Communication And Signaling; Jet Lag; Jet Lag Syndrome; Jetlag; Jetlag Syndrome; Knowledge; Lack Of Energy; Libraries; Light; Light Therapy; Luc Gene; Luciferase Gene; Luciferases; Mammals, Mice; Man (Taxonomy); Man, Modern; Marketing; Measures; Medical; Medication; Membrane; Meteorological Climate; Mice; Microarray Analysis; Microarray-Based Analysis; Mood Disorders; Moods; Murine; Mus; Mutation; Noise; Nyctohemeral Rhythm; Output; Pathway Interactions; Patients; Performance; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Preparations; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Pharmacotherapy; Phase; Photoradiation; Photoradiation Therapy; Phototherapy; Population; Prevalence; Programs (Pt); Programs [publication Type]; Promoter; Promoters (Genetics); Promotor; Promotor (Genetics); Protein Family; Reporter; Reporter Genes; Retina; Retinal Ganglion Cells; Robotics; Running; Screening Procedure; Seasonal Affective Disorder; Seasonal Mood Disorder; Sight; Signal Transduction; Signal Transduction Pathway; Signal Transduction Systems; Signaling; Sleep; Sleeplessness; Somnolence; Source; Structure Of Suprachiasmatic Nucleus; Suprachiasmatic Nucleus; Symptoms; Symptoms Of Depression; System; System, Loinc Axis 4; Testing; Therapeutic; Time; Time Zone Change Syndrome; Time Zone Syndrome; Twenty-Four Hour Rhythm; Validation; Vision; Weight Gain; Weight Increase; Woman; Work; Base; Biological Signal Transduction; Body Weight Gain; Body Weight Increase; Cell Type; Circadian; Circadian Clock; Circadian Pacemaker; Circadian Process; Climatic; Craving; Cultured Cell Line; Daily Biorhythm; Day Shift; Depressive; Depressive Symptoms; Disease/Disorder; Diurnal Variation; Drug Discovery; Drug/Agent; Experiment; Experimental Research; Experimental Study; Genome Mutation; High Throughput Screening; Hypothalamic; Increased Appetite; Increased Hunger; Interest; Luminescence; Meetings; Melanopsin; Membrane Structure; Microarray Technology; Night Shift; Night Work; Novel; Pathway; Programs; Public Health Relevance; Research Study; Response; Retinal Ganglion; Scale Up; Screening; Screenings; Seasonal Depression; Shift Work; Small Molecule; Species Difference; Success; Suprachiasmatic Nucleus; Wt Gain

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----